Anixa Biosciences (NASDAQ: ANIX) Reports Q2 2026 Financial Results: Key Takeaways for Investors
Overview
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company, released its unaudited financial results for the second quarter ended April 30, 2026. The report provides a comprehensive look at the company’s financial health, capital structure, and key activities during the period. Investors should note both the ongoing capital raises and the company’s operational performance, as these factors could influence future share price movements.
Key Financial Highlights
- Cash and Cash Equivalents: As of April 30, 2026, Anixa held \$1.48 million in cash and cash equivalents, down from \$2.22 million as of October 31, 2025. This decrease reflects ongoing operational expenses and investments in R&D.
- Total Shareholders’ Equity: Shareholders’ equity stood at \$14.48 million as of April 30, 2026, compared to \$15.16 million at the prior fiscal year-end, indicating a modest decline primarily due to operating losses.
- Net Loss: For the three months ended April 30, 2026, the company posted a net loss of \$2.52 million, or \$(0.07) per share (basic and diluted). For the six months ended April 30, 2026, the net loss was \$5.01 million, or \$(0.15) per share, reflecting continued investment in the company’s research and development pipeline.
- Common Stock Outstanding: As of June 10, 2026, Anixa had 34,023,063 shares of common stock outstanding. The company’s only class of common stock has a par value of \$0.01 per share.
- At-the-Market (ATM) Offering: Anixa raised \$1.25 million net of expenses through an at-the-market offering during the quarter, issuing 457,806 new shares. This capital raise bolstered liquidity but also increased share count, which may affect per-share metrics.
Other Notable Items
- No Preferred Stock Outstanding: The company continues to have no preferred stock issued or outstanding, which removes the risk of dilution from preferred shares.
- Stock Compensation: The company recorded \$28,000 in adjustments to additional paid-in capital related to stock options issued to consultants, reflecting ongoing use of equity incentives to retain talent and align interests.
- Employee Stock Purchase Plan: Anixa raised \$4,000 through its employee stock purchase plan, a modest but notable form of employee engagement and capital raising.
- Reporting Status: The company confirmed it is current with all SEC filing requirements and is classified as a “smaller reporting company,” not an “emerging growth company,” and is not a shell company.
Potentially Price-Sensitive Information for Shareholders
- Ongoing Net Losses and Cash Burn: The company’s net losses and declining cash reserves highlight the importance of ongoing capital access. Investors should monitor the company’s ability to raise funds and manage expenses as it continues to execute its business plan.
- Share Dilution: The continued use of at-the-market offerings and stock-based compensation has resulted in an increased share count. This may dilute existing shareholders and affect future earnings per share, a key metric for valuation.
- Capital Market Activity: The ability to raise capital through equity offerings is a positive for liquidity but may weigh on share price if investors are concerned about dilution or the need for additional financing.
Summary Table: Select Financial Data (in thousands, except per-share data)
| April 30, 2026 | October 31, 2025 | |
|---|---|---|
| Cash & Cash Equivalents | \$1,477 | \$2,217 |
| Total Shareholders’ Equity | \$14,475 | \$15,161 |
| Net Loss (Q2) | \$(2,516) | |
| Net Loss (6 months) | \$(5,010) | |
| Basic & Diluted EPS (Q2) | \$(0.07) | |
| Shares Outstanding (June 10, 2026) | 34,023,063 | |
Conclusion
Anixa Biosciences’ Q2 2026 report underscores the company’s continued investment in its research pipeline, supported by active capital raising measures. The ongoing net losses and declining cash reserves are important factors for shareholders and may impact future share price performance, especially if additional equity raises are required. The increase in share count through at-the-market offerings and stock compensation could lead to dilution concerns for existing shareholders. Investors should closely watch the company’s cash management, funding strategies, and operational milestones for any further impact on share value.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence or consult with a financial advisor before making investment decisions regarding Anixa Biosciences, Inc.
